Nutra Pharma Corp.
NPHC
$0.0003
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 184.83% | 94.70% | 72.54% | 88.44% | 82.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.83% | 94.70% | 72.54% | 88.44% | 82.77% |
| Cost of Revenue | 269.25% | 251.64% | 162.73% | 141.08% | -12.16% |
| Gross Profit | 76.19% | -79.22% | -100.51% | -43.33% | 560.98% |
| SG&A Expenses | -23.15% | 6.98% | 35.19% | 112.48% | 92.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.74% | 13.50% | 38.76% | 113.57% | 86.86% |
| Operating Income | 25.18% | -9.16% | -37.25% | -114.96% | -87.04% |
| Income Before Tax | 141.23% | 168.44% | 170.27% | -1,596.79% | -522.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 141.23% | 168.44% | 170.27% | -1,596.79% | -522.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 141.23% | 168.44% | 170.27% | -1,596.79% | -522.58% |
| EBIT | 25.18% | -9.16% | -37.25% | -114.96% | -87.04% |
| EBITDA | 25.96% | -8.47% | -36.73% | -114.88% | -86.91% |
| EPS Basic | 140.00% | 166.67% | 169.23% | -1,800.00% | -316.67% |
| Normalized Basic EPS | 135.29% | 165.52% | 166.67% | -1,100.00% | -466.67% |
| EPS Diluted | 112.82% | 130.61% | 133.96% | -450.00% | -254.55% |
| Normalized Diluted EPS | 117.39% | 138.71% | 141.18% | -500.00% | -360.00% |
| Average Basic Shares Outstanding | 4.37% | 5.71% | 7.33% | 9.46% | 15.60% |
| Average Diluted Shares Outstanding | 16.93% | 8.17% | 37.43% | -0.16% | 3.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |